mail
versión imprimible
 
 

6th Gene Therapy for Rare Disorders 2023

Evvnt Promotion / evvnt
-
20.03.2023 - 23.03.2023  Sheraton Boston Hotel, 39 Dalton St, 02199 Boston, USA
Time: 8:00 am to 5:00 pm
 
Temas de la conferencia
2022 has been a landmark year for the global gene therapy space. With August came the green light for bluebird bio's Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels we saw the accelerated approval of another bluebird bio product, Skysona. Overseas, July and August brought EMA approvals for PTC Therapeutics' Upstaza and BioMarin's Roctavian, the first gene therapies for AADC deficiency and Haemophilia A respectively.
La Sociedad Científica
Hanson Wade
Observaciones
Speakers: Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, Deborah Ascheim, Chief Medical Officer, Stridebio, Eduard Ayuso, Chief Executive and Technology Officer, DiNAQOR, Sudha Babu, Regulatory CMC Leader, Spark Therapeutics and More
 

Información e inscripción:

https://go.evvnt.com/1439816-2?pid=4832
Ms. Emily Birt
 
Categorías
Salud Pública, Servicios de salud
Idioma
Inglés
Cuota del Congreso
USD 2999.00 - USD 7095.00
Los participantes esperaban
1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

AGEM - Arbeitsgemeinschaft Ethnologie und MedizinHelix - Forschung & Beratung WienOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation Österreichisches Rotes KreuzEuropean Public Health Association (EUPHA)AMREF - African Medical and Research FoundationHilfswerk AustriaSwiss Tropical and Public Health Institute